Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations
Arthritis & Rheumatism2004Vol. 50(4), pp. 1286–1295
Citations Over TimeTop 10% of 2004 papers
Dirk Foell, Helmut Wittkowski, Inga Hammerschmidt, Nico Wulffraat, Heinrike Schmeling, Michael Frosch, Gerd Horneff, Wietse Kuis, Clemens Sorg, Johannes Roth
Abstract
S100A12 serum concentrations indicate neutrophil activation in JRA and correlate with disease activity. S100A12 may indicate synovial inflammation even when other signs of arthritis are absent. Its function as a proinflammatory factor secreted by activated neutrophils makes this protein a potential target for future therapies.
Related Papers
- Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.(2001)
- → Etanercept in Juvenile Rheumatoid Arthritis(2001)20 cited
- Etanercept therapy in children with juvenile rheumatoid arthritis.(2005)
- Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report.(2005)
- EFFECTS OF ETANERCEPT IN KOREAN PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS(2008)